42.05
+2.60
+(6.59%)
At close: April 17 at 3:30:00 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
4,641,594
3,989,561
3,020,451
2,502,898
1,927,557.55
Cost of Revenue
2,557,507
2,262,366
1,628,663
1,384,499
1,189,173.48
Gross Profit
2,084,087
1,727,195
1,391,788
1,118,399
738,384.07
Operating Expense
1,350,169
1,067,108
865,808
614,608
343,105.28
Operating Income
733,918
660,087
525,980
503,791
395,278.79
Net Non Operating Interest Income Expense
-81,164
-39,313
-10,222
-4,717
-11,632.30
Pretax Income
868,569
697,725
544,788
515,987
384,837.34
Tax Provision
173,990
125,050
109,425
115,614
82,234.43
Net Income Common Stockholders
713,366
571,802
435,362
400,373
302,602.91
Diluted NI Available to Com Stockholders
713,366
571,802
435,362
400,373
302,602.91
Basic EPS
2.17
1.81
1.42
1.54
1.31
Diluted EPS
1.78
1.54
1.42
1.54
1.31
Basic Average Shares
328,202.57
315,400
307,425
259,330
307,425
Diluted Average Shares
400,946.36
372,445
307,425
259,330
307,425
Rent Expense Supplemental
--
7,748
8,043
9,296
7,408.79
Total Expenses
3,907,676
3,329,474
2,494,471
1,999,107
1,532,278.75
Net Income from Continuing & Discontinued Operation
713,366
571,802
435,362
400,373
302,602.91
Normalized Income
714,622.30
573,101.06
439,335.44
402,288.84
302,602.91
Interest Income
--
38,366
32,704
6,989
865.03
Interest Expense
94,480
52,629
30,926
6,657
7,729.25
Net Interest Income
-81,164
-39,313
-10,222
-4,717
-11,632.30
EBIT
963,049
750,354
575,714
522,644
392,566.60
EBITDA
1,108,314
858,349
641,967
551,692
415,676.02
Reconciled Cost of Revenue
2,557,507
2,262,366
1,628,663
1,384,499
1,189,173.48
Reconciled Depreciation
145,265
107,995
66,252
29,048
23,109.42
Net Income from Continuing Operation Net Minority Interest
713,366
571,802
435,362
400,373
302,602.91
Total Unusual Items Excluding Goodwill
-1,571
-1,571
-4,983
-2,393
--
Total Unusual Items
-1,571
-1,571
-4,983
-2,393
--
Normalized EBITDA
1,109,885
859,920
646,950
554,085
415,676.02
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-314.70
-271.94
-1,009.56
-477.16
--
3/31/2021 - 11/15/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SYNCOMF.NS Syncom Formulations (India) Limited
17.56
+0.98%
SEQUENT.NS Sequent Scientific Limited
147.34
+1.60%
LASA.NS Lasa Supergenerics Limited
17.46
-0.96%
LASA.BO Lasa Supergenerics Limited
17.52
-0.57%
BALPHARMA.NS Bal Pharma Limited
104.91
-1.41%
JUBLPHARMA.BO Jubilant Pharmova Limited
919.00
+0.44%
SHUKRAPHAR.BO Shukra Pharmaceuticals Limited
19.50
-4.97%
NECLIFE.BO Nectar Lifesciences Limited
22.82
-0.31%
GLAND.BO Gland Pharma Limited
1,448.25
+0.35%
REMLIFE.BO Remedium Lifecare Limited
1.6400
+1.86%